Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (OTCPK:ADXS)

Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

GlobeNewswire 8 days ago

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

GlobeNewswire March 26, 2024

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

GlobeNewswire February 20, 2024

Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

GlobeNewswire February 6, 2024

Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors

GlobeNewswire November 6, 2023

Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023

GlobeNewswire October 23, 2023

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

GlobeNewswire October 19, 2023

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 10, 2023

Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023

GlobeNewswire August 1, 2023

Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement

GlobeNewswire July 27, 2023

Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors

GlobeNewswire July 5, 2023

Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 5, 2023

Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 25, 2023

Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 23, 2023

Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 27, 2023

Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee

GlobeNewswire March 3, 2023

Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

GlobeNewswire February 10, 2023

Advaxis and Ayala Pharmaceuticals Complete Merger

GlobeNewswire January 19, 2023

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

GlobeNewswire January 12, 2023

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Advaxis, Inc. (ADXS)

Newsfile October 19, 2022